Pepsinogen I as a marker of risk of gastric mucosal cell destruction in Helicobacter pylori-infected patients taking acetylsalicylic acid
Background. Antiplatelet therapy is a major component of the treatment in patients at high risk of cardiovascular complications. Antiplatelet agents that are used to prevent blood clots can have several adverse effects on the gastrointestinal tract, such as bleeding and ulcers. An additional factor...
Saved in:
Main Authors: | I.G. Paliy, S.V. Zaika, А.G. Каpitun, О.М. Muzychuk |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaslavsky O.Yu.
2025-06-01
|
Series: | Gastroenterologìa |
Subjects: | |
Online Access: | https://gastro.zaslavsky.com.ua/index.php/journal/article/view/670 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum Assay Findings after Successful Helicobacter pylori Eradication
by: Sun-Young Lee
Published: (2021-12-01) -
Helicobacter Pylori Antral Gastritis on Spa Treatmen Level
by: Y. S. Osipov, et al.
Published: (2012-09-01) -
A Prospective Study on the Detection of Gastric Neoplasms Using Pepsinogen and Gastrin-17 Levels
by: Sun-Young Lee, et al.
Published: (2025-07-01) -
ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID
by: I. N. Bokarev, et al.
Published: (2016-01-01) -
<i>H. pylori</i> eradication therapy for patients receiving nonsteroid antiinflammatory drugs
by: V. T. Ivashkin, et al.
Published: (2012-11-01)